NCT02260011View on ClinicalTrials.gov

Study of the Comparability of Ipratropium Bromide Hydrofluoroalkane (HFA)-134a Inhalation Aerosol to the Market Standard, Atrovent® Chlorofluorocarbon (CFC) Inhalation Aerosol, in Patients With Chronic Obstructive Pulmonary Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

October 31, 2000

Primary Completion Date

February 28, 2001

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

Ipratropium bromide HFA-134a inhalation aerosol

DRUG

Atrovent® CFC inhalation aerosol

DRUG

Placebo

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT02260011 - Study of the Comparability of Ipratropium Bromide Hydrofluoroalkane (HFA)-134a Inhalation Aerosol to the Market Standard, Atrovent® Chlorofluorocarbon (CFC) Inhalation Aerosol, in Patients With Chronic Obstructive Pulmonary Disease | Biotech Hunter | Biotech Hunter